» Articles » PMID: 17034586

Interferon-gamma is Causatively Involved in Experimental Inflammatory Bowel Disease in Mice

Overview
Date 2006 Oct 13
PMID 17034586
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

Cytokines may be crucially involved in the pathogenesis of inflammatory bowel diseases (IBD), but it remains controversial whether interferon (IFN)-gamma, a typical proinflammatory cytokine, is an essential mediator to cause the disorders. In the present study, IFN-gamma(-/-) and wild-type (WT) C57BL/6 mice were fed 2.5% dextran sodium sulphate (DSS) in drinking water for 7 days, in order to investigate DSS-induced intestinal inflammation. The DSS-treated WT mice exhibited a robust production of IFN-gamma in the gut, a remarkable loss of body weight, as well as high rate of mortality (60%). In striking contrast, IFN-gamma deficient mice did not develop DSS-induced colitis, as indicated by the maintenance of body weight and survival rate of 100%. Severe intestinal inflammation was demonstrated exclusively in WT animals in terms of the shortening of the bowel as well as the elevation of the disease activity index, myeloperoxidase (MPO) activity and serum haptoglobin level. Histological study of DSS-treated WT intestine revealed disruption of mucosal epithelium and massive infiltration of inflammatory cells, while the organ from IFN-gamma(-/-) mice remained virtually normal in appearance. Enzyme-linked immunosorbent assay (ELISA) analyses indicated abundant production of three chemokines, i.e. monokine induced by interferon-gamma (MIG), interferon-inducible protein 10 (IP-10) and monocyte chemoattractant protein-1 (MCP-1), in the DSS-irritated intestine of WT but not of IFN-gamma(-/-) mice. The present results demonstrate clearly that IFN-gamma plays indispensable roles in the initiation of DSS colitis, and some chemokines are produced in an IFN-gamma-dependent fashion.

Citing Articles

Characterization of post-inflammatory irritable bowel syndrome animal model following acute colitis recovery.

Jeong E, Jung H, Choi E, Yun K, Lee A, Kim Y Sci Rep. 2025; 15(1):8512.

PMID: 40075091 PMC: 11904205. DOI: 10.1038/s41598-025-88981-7.


Gut Microbiota and Metabolites Mediate Health Benefits of Oat and Oat Bran Consumption in IBD Mice.

Duan W, Zheng B, Li T, Liu R Nutrients. 2025; 16(24.

PMID: 39770986 PMC: 11676952. DOI: 10.3390/nu16244365.


Spatial profiling of the mouse colonic immune landscape associated with colitis and sex.

Holm M, Stepanauskaite L, Backstrom A, Birgersson M, Socciarelli F, Archer A Commun Biol. 2024; 7(1):1595.

PMID: 39613949 PMC: 11606951. DOI: 10.1038/s42003-024-07276-1.


Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.

Ohara D, Takeuchi Y, Hirota K Cell Mol Immunol. 2024; 21(11):1183-1200.

PMID: 39379604 PMC: 11528014. DOI: 10.1038/s41423-024-01218-x.


Epithelial-specific loss of Smad4 alleviates the fibrotic response in an acute colitis mouse model.

Hashemi Z, Hui T, Wu A, Matouba D, Zukowski S, Nejati S Life Sci Alliance. 2024; 7(12).

PMID: 39366762 PMC: 11452480. DOI: 10.26508/lsa.202402935.


References
1.
Tagawa Y, Sekikawa K, Iwakura Y . Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol. 1997; 159(3):1418-28. View

2.
Byrne F, Viney J . Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Devel. 2006; 9(2):207-17. View

3.
Macdermott R, Sanderson I, Reinecker H . The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 1998; 4(1):54-67. DOI: 10.1097/00054725-199802000-00009. View

4.
Rogler G, Andus T . Cytokines in inflammatory bowel disease. World J Surg. 1998; 22(4):382-9. DOI: 10.1007/s002689900401. View

5.
Ohkusa T, Okayasu I, Tokoi S, Araki A, Ozaki Y . Changes in bacterial phagocytosis of macrophages in experimental ulcerative colitis. Digestion. 1995; 56(2):159-64. DOI: 10.1159/000201236. View